Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 590-596

  Ridruejo, E ^a,b   Marciano, S ^c   Galdame, O ^c   Reggiardo, M V ^d   Munoz A E ^e   Adrover, R ^f   Cocozzella, D ^f   Fernandez, N ^g   Estepo, C ^h   Mendizabal M ^b   Romero, G A ^e   Levi, D ^e   Schroder, T ^h   Paz, S ^h   Fainboim, H ^h   Mando O G ^a   Gadano, A C ^c   Silva, M O ^b  

^a CEMIC   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d Hospital Centenario de Rosario   (Argentina)

^e HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^f Hepatology Unit Centro de Hepatología La Plata Provincia de Buenos Aires   (Argentina)

^g HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^h HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

chronic hepatitis B; entecavir; routine clinical practice; treatment; virological relapse

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROCONVERSION; AGED; ANALOGS AND DERIVATIVES; BLOOD; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84903817465     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12200     Document Type: Article

References (19)

1. Lavanchy D, Hepatitis B,. Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. (Pubitemid 38365759)
2. World Health Organization. Hepatitis B Fact Sheet No. 204. 2012.
3. Lok ASF, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
5. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH,. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-212. (Pubitemid 36005519)
6. van Nunen AB, Hansen BE, Suh DJ, et al,. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424. (Pubitemid 36250065)
7. Yoon SK, Jang JW, Kim CW, et al,. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005; 48: 341-349.
8. Kuo YH, Chen CH, Wang JH, et al,. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol 2010; 45: 75-81.
9. Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HLA,. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-498.
10. Heathcote EJ, Marcellin P, Buti M, et al,. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
11. Lampertico P, Soffredini R, Vigano M, et al,. 5-year entecavir treatment in NUC-naive, field-practice patients with chronic hepatitis b showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics. Amsterdam, The Netherlands: Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver, 2013. Abstract 755.
12. Lampertico P, Soffredini R, Vigano M, et al,. Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months. Barcelona, Spain: Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver, 2012. Abstract 525.
13. Yao GB, Ren H, Xu DZ, et al,. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepat 2010; 17 (Suppl. 1): 51-58.
14. Song MJ, Song do S, Kim HY, et al,. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18: 6277-6283.
15. Liang Y, Jiang J, Su M, et al,. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34: 344-352.
16. Liaw YF, Leung NW, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
17. Chein RN, Yeh CT, Tsai SL, Chu CM, Liaw YF,. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-1273.
18. Ryu SH, Chung YH, Choi MH, et al,. Long-term additional lamivudine therapy enhances durability of lamivudineinduced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614-619. (Pubitemid 37204663)
19. Cai W, Xie Q, An B, et al,. On-treatment serum HBsAg level is predictive of sustained off-treatment virological response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-26.